These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34516243)

  • 1. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
    Li D; Sabato PE; Guiastrennec B; Ouerdani A; Feng HP; Duval V; De Anda CS; Sears PS; Chou MZ; Hardalo C; Broyde N; Rizk ML
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0089521. PubMed ID: 34516243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
    Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
    Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
    Lodise TP; Fang E; Minassian SL; Prokocimer PG
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.
    Ferrández O; Urbina O; Grau S
    Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.
    Arrieta AC; Ang JY; Espinosa C; Fofanov O; Tøndel C; Chou MZ; De Anda CS; Kim JY; Li D; Sabato P; Sears PS; Bradley JS
    Pediatr Infect Dis J; 2021 Apr; 40(4):317-323. PubMed ID: 33710976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
    Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
    Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.